Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
ConditionCannabis Use Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorNational Institute on Drug Abuse (NIDA)
About this trial
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Eligibility criteria
Qualifiers
Between 18 and 70 years of age
Meets DSM-5 criteria for moderate or severe CUD
Interested in treatment for cannabis use disorder
Able to understand the study procedures and written informed consent in English
Disqualifiers
Body Mass Index (BMI) ≤ 23 kg/m²
Presence of a medical or psychiatric disorder that contraindicates participation in the study
Substance use disorder other than tobacco or mild alcohol-use disorder
Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product
Trial design
Treatments tested in this trial
- Tirzepatide
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov